EBMT Centre Identification Code (CIC): _ _ _ _
Hospital Unique Patient Number (UPN): _ _ _ _ _ _ _ _ _ _ _ _
Patient Number in EBMT Registry: _ _ _ _ _ _ _ _ _

Treatment Type ☐ CT
Treatment Date _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)*

CELLULAR THERAPIES
--- Day 100, 6 Months, Annual & Unscheduled Follow-Up ---

SURVIVAL STATUS

Date of follow-up _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)*
(if died: date of death, if lost to follow up: date last seen)

Survival status:

☐ Alive
☐ Dead
☐ Lost to follow-up

Assessment period covered by this report:

☐ Day 100
☐ 6 Months
☐ Annual or unscheduled follow-up

Main cause of death:
(check only one main cause)

☐ Relapse or progression/persistent disease

☐ Secondary malignancy

☐ CT-related

☐ HCT-related

☐ GT-related

☐ IST-related

Select treatment related cause: *(select all that apply)*
☐ Graft versus Host Disease
☐ Non-infectious complication
☐ Infectious complication:
(select all that apply)
☐ Bacterial infection
☐ Viral infection
☐ Fungal infection
☐ Parasitic infection
☐ Infection with unknown pathogen
☐ Other treatment related cause of death; specify: _____

☐ Unknown

☐ Other cause of death; specify: _____

Extended dataset

Autopsy performed:

☐ No
☐ Yes
☐ Unknown

BEST RESPONSE

Complete only for Day 100,6 Months and first annual Follow-Up.
Not applicable for Inborn Errors

Best clinical/biological response after this CT* *(observed before any subsequent treatment)*: _____

Date best response first observed: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

* Indicate the best clinical/biological response after CT corresponding to indication diagnosis for CT was given by selecting from the list provided in Appendix 1

RECOVERY

Complete only for Day 100 Follow-Up and 6 Months Follow-up.

If the recovery occurred before 100 days and was reported at Day 100 Follow-up the section can be skipped at 6 Months Follow-up.

Absolute neutrophil count (ANC) recovery *(neutrophils ≥ 0.5x10^9 /L)*:

☐ No: **Date of the last assessment:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)*

☐ Yes: **Date of ANC recovery:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)*
(first of 3 consecutive values after 7 days without transfusion containing neutrophils)

☐ Never below

☐ Not evaluated

☐ Unknown

Did the patient receive granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF during this follow-up period?

☐ No

☐ Yes: **Start date:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

Stop date: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Ongoing ☐ Unknown

☐ Unknown

Platelet reconstitution *(platelets ≥ 20x10^9 /L:)*:

☐ No: **Date of the last assessment:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

☐ Yes: **Date of platelet reconstitution:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown
(first of 3 consecutive values after 7 days without platelet transfusion)

☐ Never below

☐ Not evaluated

☐ Unknown

Date of the last platelet transfusion: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Not applicable *(not transfused)* ☐ Unknown

Was B-cell count monitored during this follow-up period ?

☐ No

☐ Yes: **Please provide the absolute total immune cell count:** _____ ☐ 10^9/L ☐ 10^6/L (cells/µL)

Please provide the absolute B-cell count: _____ ☐ 10^9/L ☐ 10^6/L (cells/µL)

Date of immune cell assessment: _ _ _ _ / _ _ / _ _ ***(YYYY/MM/DD)***

☐ Unknown

CURRENT HAEMATOLOGICAL FINDINGS

Hb (g/dL)	_____	☐ Not evaluated	☐ Unknown
Platelets (10^9/L)	_____	☐ Not evaluated	☐ Unknown
Were platelets transfused within 7 days before assessment?		☐ No ☐ Yes	☐ Unknown
White blood cells (10^9/L)	_____	☐ Not evaluated	☐ Unknown
Lymphocytes	_____ % **OR** Absolute count: _____ 10^9 /L	☐ Not evaluated	☐ Unknown
Neutrophils	_____ % **OR** Absolute count: _____ 10^9 /L	☐ Not evaluated	☐ Unknown

Extended dataset

Antimicrobial prophylaxis

Did the patient receive prophylaxis for bacterial, viral or fungal infection during this follow-up period? ☐ No ☐ Yes

If yes, what type of prophylaxis? ☐ Antibacterial ☐ Antifungal ☐ Antiviral
(select all that apply and complete the relevant section)

Antibacterial prophylaxis

Antibiotic *(select all that were administered)*	**Phase** *Day 100 0nly*	**Responses for > 100 days only**
☐ Ciprofloxacin	☐ Pre-ANC recovery ☐ Post-ANC recovery; ☐ Only post-ANC recovery ☐ Started pre-ANC recovery and continued into post-ANC recovery ☐ Started and stopped in pre-ANC recovery phase and restarted in post-ANC recovery phase ☐ Unknown	☐ Started in this follow-up period; **Start date:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown ☐ Ongoing since previous follow-up ☐ Unknown
☐ Levofloxacin	☐ Pre-ANC recovery ☐ Post-ANC recovery; ☐ Only post-ANC recovery ☐ Started pre-ANC recovery and continued into post-ANC recovery ☐ Started and stopped in pre-ANC recovery phase and restarted in post-ANC recovery phase ☐ Unknown	☐ Started in this follow-up period; **Start date:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown ☐ Ongoing since previous follow-up ☐ Unknown
☐ Moxifloxacin	☐ Pre-ANC recovery ☐ Post-ANC recovery; ☐ Only post-ANC recovery ☐ Started pre-ANC recovery and continued into post-ANC recovery ☐ Started and stopped in pre-ANC recovery phase and restarted in post-ANC recovery phase ☐ Unknown	☐ Started in this follow-up period; **Start date:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown ☐ Ongoing since previous follow-up ☐ Unknown
☐ Penicillin/ Amoxicillin	☐ Pre-ANC recovery ☐ Post-ANC recovery; ☐ Only post-ANC recovery ☐ Started pre-ANC recovery and continued into post-ANC recovery ☐ Started and stopped in pre-ANC recovery phase and restarted in post-ANC recovery phase ☐ Unknown	☐ Started in this follow-up period; **Start date:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown ☐ Ongoing since previous follow-up ☐ Unknown

Extended dataset

Antibacterial prophylaxis

Antibiotic *(select all that were administered)*	**Phase** *Day 100 only*	**Responses for > 100 days only**
☐ Ampicillin clavulanate	☐ Pre-ANC recovery ☐ Post-ANC recovery; ☐ Only post-ANC recovery ☐ Started pre-ANC recovery and continued into post-ANC recovery ☐ Started and stopped in pre-ANC recovery phase and restarted in post-ANC recovery phase ☐ Unknown	☐ Started in this follow-up period; **Start date:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown ☐ Ongoing since previous follow-up ☐ Unknown
☐ Non-absorbable antibiotic	☐ Pre-ANC recovery ☐ Post-ANC recovery; ☐ Only post-ANC recovery ☐ Started pre-ANC recovery and continued into post-ANC recovery ☐ Started and stopped in pre-ANC recovery phase and restarted in post-ANC recovery phase ☐ Unknown	☐ Started in this follow-up period; **Start date:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown ☐ Ongoing since previous follow-up ☐ Unknown

Final date antibacterial prophylaxis was discontinued: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Ongoing ☐ Unknown

Extended dataset

Antiviral prophylaxis

Did the patient receive cytomegalovirus (CMV) prophylaxis during this follow-up period?

☐ No

☐ Yes: **Which drugs were used?** *(select all that apply)*

- ☐ High-dose acyclovir (≥500 mg/m2/8h (IV) with normal renal function or ≥ 800 mg/6h (oral) with normal renal function)
- ☐ High-dose valaciclovir (2 grams Q8 hours with normal renal function)
- ☐ Ganciclovir intravenous
- ☐ Valganciclovir
- ☐ Foscarnet
- ☐ Maribavir
- ☐ CMV immunoglobulin
- ☐ Letermovir
- ☐ Other drug

Final date CMV prophylaxis was discontinued: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Ongoing ☐ Unknown

Did the patient receive prophylaxis for varicella-zoster virus (VZV) or herpes simplex virus (HSV) with either acyclovir or valaciclovir during this follow-up period?

☐ No

☐ Yes: **Final date VZV or HSV prophylaxis was discontinued:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Ongoing ☐ Unknown

Did the patient receive rituximab or another anti-CD20 monoclonal drug as prophylaxis for Epstein-Barr virus post-transplant lymphoproliferative disorder (EBV-PTLD) during this follow-up period?

☐ No

☐ Yes

Did the patient receive prophylaxis for hepatitis B virus (HBV) during this follow-up period?

☐ No

☐ Yes: **Which drugs were used?** *(select all that apply)*

- ☐ Lamivudine
- ☐ Entecavir
- ☐ Tenofovir
- ☐ HBV immunoglobulin
- ☐ Other drug

Final date HBV prophylaxis was discontinued: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Ongoing ☐ Unknown

Extended dataset

Antifungal prophylaxis

Antifungal *(select all that were administered)*	**Phase** *Day 100 0nly*	**Responses for > 100 days only**
☐ Fluconazole	☐ Pre-ANC recovery ☐ Post-ANC recovery; ☐ Only post-ANC recovery ☐ Started pre-ANC recovery and continued into post-ANC recovery ☐ Started and stopped in pre-ANC recovery phase and restarted in post-ANC recovery phase ☐ Unknown	☐ Started in this follow-up period; **Start date:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown ☐ Ongoing since previous follow-up ☐ Unknown
☐ Voriconazole	☐ Pre-ANC recovery ☐ Post-ANC recovery; ☐ Only post-ANC recovery ☐ Started pre-ANC recovery and continued into post-ANC recovery ☐ Started and stopped in pre-ANC recovery phase and restarted in post-ANC recovery phase ☐ Unknown	☐ Started in this follow-up period; **Start date:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown ☐ Ongoing since previous follow-up ☐ Unknown
☐ Posaconazole	☐ Pre-ANC recovery ☐ Post-ANC recovery; ☐ Only post-ANC recovery ☐ Started pre-ANC recovery and continued into post-ANC recovery ☐ Started and stopped in pre-ANC recovery phase and restarted in post-ANC recovery phase ☐ Unknown	☐ Started in this follow-up period; **Start date:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown ☐ Ongoing since previous follow-up ☐ Unknown
☐ Itraconazole	☐ Pre-ANC recovery ☐ Post-ANC recovery; ☐ Only post-ANC recovery ☐ Started pre-ANC recovery and continued into post-ANC recovery ☐ Started and stopped in pre-ANC recovery phase and restarted in post-ANC recovery phase ☐ Unknown	☐ Started in this follow-up period; **Start date:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown ☐ Ongoing since previous follow-up ☐ Unknown
☐ Isavuconazole	☐ Pre-ANC recovery ☐ Post-ANC recovery; ☐ Only post-ANC recovery ☐ Started pre-ANC recovery and continued into post-ANC recovery ☐ Started and stopped in pre-ANC recovery phase and restarted in post-ANC recovery phase ☐ Unknown	☐ Started in this follow-up period; **Start date:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown ☐ Ongoing since previous follow-up ☐ Unknown

Antifungal prophylaxis

Antifungal *(select all that were administered)*	**Phase** *Day 100 0nly*	**Responses for > 100 days only**
☐ Caspofungin	☐ Pre-ANC recovery ☐ Post-ANC recovery; ☐ Only post-ANC recovery ☐ Started pre-ANC recovery and continued into post-ANC recovery ☐ Started and stopped in pre-ANC recovery phase and restarted in post-ANC recovery phase ☐ Unknown	☐ Started in this follow-up period; **Start date:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown ☐ Ongoing since previous follow-up ☐ Unknown
☐ Micafungin	☐ Pre-ANC recovery ☐ Post-ANC recovery; ☐ Only post-ANC recovery ☐ Started pre-ANC recovery and continued into post-ANC recovery ☐ Started and stopped in pre-ANC recovery phase and restarted in post-ANC recovery phase ☐ Unknown	☐ Started in this follow-up period; **Start date:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown ☐ Ongoing since previous follow-up ☐ Unknown
☐ Anidulafungin	☐ Pre-ANC recovery ☐ Post-ANC recovery; ☐ Only post-ANC recovery ☐ Started pre-ANC recovery and continued into post-ANC recovery ☐ Started and stopped in pre-ANC recovery phase and restarted in post-ANC recovery phase ☐ Unknown	☐ Started in this follow-up period; **Start date:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown ☐ Ongoing since previous follow-up ☐ Unknown
☐ Ambisome (IV or inhalations)	☐ Pre-ANC recovery ☐ Post-ANC recovery; ☐ Only post-ANC recovery ☐ Started pre-ANC recovery and continued into post-ANC recovery ☐ Started and stopped in pre-ANC recovery phase and restarted in post-ANC recovery phase ☐ Unknown	☐ Started in this follow-up period; **Start date:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown ☐ Ongoing since previous follow-up ☐ Unknown
☐ Rezafungin	☐ Pre-ANC recovery ☐ Post-ANC recovery; ☐ Only post-ANC recovery ☐ Started pre-ANC recovery and continued into post-ANC recovery ☐ Started and stopped in pre-ANC recovery phase and restarted in post-ANC recovery phase ☐ Unknown	☐ Started in this follow-up period; **Start date:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown ☐ Ongoing since previous follow-up ☐ Unknown

Final date antifungal prophylaxis was discontinued: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Ongoing ☐ Unknown

Extended dataset

Antifungal prophylaxis

Did the patient receive prophylaxis for *Pneumocystis jirovecii* pneumonia (PJP) during this follow-up period?

☐ No

☐ Yes: **Which drugs were used?** *(select all that apply)*

- ☐ Trimethoprim-sulfamethoxazole
- ☐ Dapsone
- ☐ Atovaquone
- ☐ Pentamidine inhaled
- ☐ Pentamidine intravenous
- ☐ Other drug

Final date prophylaxis was discontinued: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Ongoing ☐ Unknown

☐ Unknown

Preventive therapies

Were any immunoglobulins administered during this follow-up period?

☐ No

☐ Yes: **Start date:**_ _ _ _ / _ _ / _ _ (YYYY/MM/DD) ☐ Unknown

Stop date:_ _ _ _ / _ _ / _ _ (YYYY/MM/DD) ☐ Ongoing ☐ Unknown

COMPLICATIONS SINCE THE LAST REPORT
-- GvHD --

Do not report complications that were resolved before this cellular therapy.
Do not report complications that were previously reported as resolved, unless they recurred.

Did graft versus host disease (GvHD) occur during this follow-up period?

☐ No *(proceed to 'Complications since the last report - Non-infectious complications')*

☐ Yes: **Did the patient receive a systemic/immunosuppressive treatment for GvHD during this follow-up period?**
- ☐ No
- ☐ Yes: ☐ Started in this follow-up period; **Date treatment started:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown
  - ☐ Ongoing since previous follow-up
  - **Treatment stopped:** ☐ No
    - ☐ Yes; **Stop date of treatment:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown
    - ☐ Unknown
- ☐ Unknown

☐ Unknown *(proceed to 'Complications since the last report - Non-infectious complications')*

Did acute GvHD occur during this follow-up period?

☐ No

☐ Yes: ☐ Started in this follow-up period; **Date of onset:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown
- ☐ Ongoing since previous follow-up

Maximum observed organ severity score during this period:

Skin:	☐ 0 *(none)*	☐ 1	☐ 2	☐ 3	☐ 4	☐ Not evaluated	☐ Unknown
Liver:	☐ 0 *(none)*	☐ 1	☐ 2	☐ 3	☐ 4	☐ Not evaluated	☐ Unknown
Lower GI tract:	☐ 0 *(none)*	☐ 1	☐ 2	☐ 3	☐ 4	☐ Not evaluated	☐ Unknown
Upper GI tract:	☐ 0 *(none)*	☐ 1	☐ 2	☐ 3	☐ 4	☐ Not evaluated	☐ Unknown
Other site affected:	☐ No	☐ Yes; specify: _____					

Overall maximum grade observed during this period: ☐ 1 ☐ 2 ☐ 3 ☐ 4 ☐ Not evaluated ☐ Unknown

Steroid-refractory acute GvHD: ☐ No
- ☐ Yes: ☐ Started in this follow-up period; **Date of onset:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown
  - ☐ Ongoing since previous follow-up
- ☐ Unknown

Extended dataset

aGvHD resolved: (Resolution of symptoms) ☐ No ☐ Yes; **Date of aGvHD resolution:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* (Resolution of symptoms) ☐ Unknown ☐ Unknown

☐ Unknown

COMPLICATIONS SINCE THE LAST REPORT continued
-- GvHD --

Did chronic GvHD occur during this follow-up period?

☐ No

☐ Yes: ☐ Started in this follow-up period; **Date of onset:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

☐ Ongoing since previous follow-up

Maximum NIH score during <u>this period</u>:
☐ Mild
☐ Moderate
☐ Severe
☐ Unknown
☐ Not evaluated

Date of maximum NIH score: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

Maximum observed organ severity score during <u>this period</u>:

Skin:	☐ 0 *(none)*	☐ 1	☐ 2	☐ 3	☐ 4	☐ Not evaluated	☐ Unknown
Oral:	☐ 0 *(none)*	☐ 1	☐ 2	☐ 3	☐ 4	☐ Not evaluated	☐ Unknown
Gastrointestinal:	☐ 0 *(none)*	☐ 1	☐ 2	☐ 3	☐ 4	☐ Not evaluated	☐ Unknown
Eyes:	☐ 0 *(none)*	☐ 1	☐ 2	☐ 3	☐ 4	☐ Not evaluated	☐ Unknown
Liver:	☐ 0 *(none)*	☐ 1	☐ 2	☐ 3	☐ 4	☐ Not evaluated	☐ Unknown
Joints and fascia:	☐ 0 *(none)*	☐ 1	☐ 2	☐ 3	☐ 4	☐ Not evaluated	☐ Unknown
Lungs:	☐ 0 *(none)*	☐ 1	☐ 2	☐ 3	☐ 4	☐ Not evaluated	☐ Unknown
Genitalia:	☐ 0 *(none)*	☐ 1	☐ 2	☐ 3	☐ 4	☐ Not evaluated	☐ Unknown
Other site affected:	☐ No	☐ Yes; specify: _____					

Steroid-refractory chronic GvHD: ☐ No

☐ Yes: ☐ Started in this follow-up period;

☐ Ongoing since previous follow-up

☐ Unknown

Date of onset: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)*
☐ Unknown

Extended dataset

cGvHD resolved: (Resolution of symptoms) ☐ No ☐ Yes; ☐ Unknown

Date of cGvHD resolution: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown
(Resolution of symptoms)

Was overlap syndrome observed: *(features of both chronic and acute GvHD)* ☐ No ☐ Yes ☐ Unknown

☐ Unknown

COMPLICATIONS SINCE THE LAST REPORT
-- Non-infectious complications --

Do not report complications that were resolved before this cellular therapy.
Do not report complications that were previously reported as resolved, unless they recurred.

Did non-infectious complications occur or continue during this follow-up period?

☐ No (*proceed to 'Complications since the last report - Infectious complications')*
☐ Yes (report in the table below)
☐ Unknown

Cytokine release syndrome (CRS)

Complication observed during this follow-up period? ☐ No
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

Maximum grade observed during this period: ☐ 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 (fatal) ☐ Unknown

Grading system:
☐ ASTCT consensus (Lee 2019)
☐ Penn
☐ CTCAE
☐ Lee 2014
☐ MDACC
☐ Other; specify: _____

Onset date (*YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Was the CRS treated? ☐ No
☐ Yes; specify treatment_____
☐ Unknown

Resolved: ☐ No
☐ Yes; **Stop date (***YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

IEC-associated neurotoxicity syndrome (ICANS)

Complication observed during this follow-up period? ☐ No
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

Maximum grade observed during this period: ☐ 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 (fatal) ☐ Unknown

Grading system:
☐ ASTCT consensus (Lee 2019)
☐ CTCAE
☐ Lee 2014
☐ MDACC
☐ Other; specify: _____

Onset date (*YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Was the ICANS treated? ☐ No
☐ Yes; specify treatment_____
☐ Unknown

Resolved: ☐ No
☐ Yes; **Stop date (***YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

COMPLICATIONS SINCE THE LAST REPORT
-- Non-infectious complications --

Other neurotoxicity observed during this follow-up period? ☐ No*
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

Specify:_____

Maximum CTCAE grade observed during this period: ☐ 3 ☐ 4 ☐ 5 (fatal) ☐ Unknown

Onset date (*YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Resolved: ☐ No
☐ Yes; **Stop date (***YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

Macrophage activation syndrome (MAS)

Complication observed during this follow-up period? ☐ No*
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

Maximum CTCAE grade observed during this period: ☐ 3 ☐ 4 ☐ 5 (fatal) ☐ Unknown

Onset date (*YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Resolved: ☐ No
☐ Yes; **Stop date (***YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

Secondary haemophagocytic lymphohistiocytosis

Complication observed during this follow-up period? ☐ No
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

Maximum CTCAE grade observed during this period: ☐ 3 ☐ 4 ☐ 5 (fatal) ☐ Unknown

Onset date (*YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Resolved: ☐ No
☐ Yes; **Stop date (***YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

Organ toxicity: skin

Complication observed during this follow-up period? ☐ No
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

Maximum CTCAE grade observed during this period: ☐ 3 ☐ 4 ☐ 5 (fatal) ☐ Unknown

Onset date (*YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Resolved: ☐ No
☐ Yes; **Stop date (***YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

*Grade 0-2

COMPLICATIONS SINCE THE LAST REPORT
-- Non-infectious complications --

Organ toxicity: liver

Complication observed during this follow-up period? ☐ No*
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

Maximum CTCAE grade observed during this period: ☐ 3 ☐ 4 ☐ 5 (fatal) ☐ Unknown

Onset date (*YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Resolved: ☐ No
☐ Yes; **Stop date (***YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

Organ toxicity: lung

Complication observed during this follow-up period? ☐ No*
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

Maximum CTCAE grade observed during this period: ☐ 3 ☐ 4 ☐ 5 (fatal) ☐ Unknown

Onset date (*YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Resolved: ☐ No
☐ Yes; **Stop date (***YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

Organ toxicity: heart

Complication observed during this follow-up period? ☐ No*
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

Maximum CTCAE grade observed during this period: ☐ 3 ☐ 4 ☐ 5 (fatal) ☐ Unknown

Onset date (*YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Resolved: ☐ No
☐ Yes; **Stop date (***YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

Organ toxicity: kidney

Complication observed during this follow-up period? ☐ No*
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

Maximum CTCAE grade observed during this period: ☐ 3 ☐ 4 ☐ 5 (fatal) ☐ Unknown

Onset date (*YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Resolved: ☐ No
☐ Yes; **Stop date (***YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

* Grade 0-2

COMPLICATIONS SINCE THE LAST REPORT
-- Non-infectious complications --

Organ toxicity: gastrointestinal

Complication observed during this follow-up period? ☐ No*
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

Maximum CTCAE grade observed during this period: ☐ 3 ☐ 4 ☐ 5 (fatal) ☐ Unknown

Onset date (*YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Resolved: ☐ No
☐ Yes; **Stop date (***YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

Other organ toxicity observed during this follow-up period? ☐ No*
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

Organ specify:_____

Maximum CTCAE grade observed during this period: ☐ 3 ☐ 4 ☐ 5 (fatal) ☐ Unknown

Onset date (*YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Resolved: ☐ No
☐ Yes; **Stop date (***YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

Tumour lysis syndrome

Complication observed during this follow-up period? ☐ No*
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

Maximum CTCAE grade observed during this period: ☐ 3 ☐ 4 ☐ 5 (fatal) ☐ Unknown

Onset date (*YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Resolved: ☐ No
☐ Yes; **Stop date (***YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

B-cell aplasia

Complication observed during this follow-up period? ☐ No
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

% B-cells: ____ ☐ Not evaluated

Onset date (*YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Resolved: ☐ No
☐ Yes; **Stop date (***YYYY/MM/DD***):** _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

* Grade 0-2

COMPLICATIONS SINCE THE LAST REPORT
-- Non-infectious complications --

Bone marrow aplasia

Complication observed during this follow-up period? ☐ No
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

Onset date (*YYYY/MM/DD*): _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Resolved: ☐ No
☐ Yes; **Stop date** (*YYYY/MM/DD*): _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

Hypogammaglobulinemia

Complication observed during this follow-up period? ☐ No*
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

Was it also present at time of the cellular therapy? ☐ No, occurred after the cellular therapy
☐ Yes: **Was it worsened by the cellular therapy?** ☐ No ☐ Yes

Onset date (*YYYY/MM/DD*): _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Resolved: ☐ No
☐ Yes; **Stop date** (*YYYY/MM/DD*): _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

Exacerbation of existing neurological disorder observed during this follow-up period? ☐ No*
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

Specify:_____
(Indicate CTCAE term)

Maximum CTCAE grade observed during this period: ☐ 3 ☐ 4 ☐ 5 (fatal) ☐ Unknown

Onset date (*YYYY/MM/DD*): _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Resolved: ☐ No
☐ Yes; **Stop date** (*YYYY/MM/DD*): _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

Other complication observed during this follow-up period? ☐ No*
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment
☐ Unknown

Specify: _____ *Consult appendix 4 for a list of complications that should not be reported*
(Indicate CTCAE term)

Maximum CTCAE grade observed during this period: ☐ 3 ☐ 4 ☐ 5 (fatal) ☐ Unknown

Onset date (*YYYY/MM/DD*): _ _ _ _ / _ _ / _ _ ☐ Unknown *Only if newly developed*

Resolved: ☐ No
☐ Yes; **Stop date** (*YYYY/MM/DD*): _ _ _ _ / _ _ / _ _ ☐ Unknown
☐ Unknown

*Grade 0-2

If more other complications occurred, copy and fill-in this table as many times as necessary.

COMPLICATIONS SINCE THE LAST REPORT
-- Infectious complications --

Do not report infections that were already reported as resolved on the previous assessment and did not reoccur.

Did infectious complications occur during the follow-up period?

☐ No *Consult appendix 4 for a list of complications that should not be reported*
☐ Yes (*report all infection-related complications below*)
☐ Unknown

Bacterial infection: ☐ No ☐ Yes ☐ Unknown

New or ongoing: ☐ Newly developed ☐ Ongoing since previous assessment

Start date: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD) only if newly developed* ☐ Unknown

☐ Gram-positive ☐ Gram-negative ☐ Other

Pathogen*: _____

Extended dataset

Carbapenem (any of imipenem, meropenem, doripenem) resistance/susceptibility:
(Only if pathogen 'Acinetobacter baumannii', 'Acinetobacter lwofii', 'Acinetobacter other', 'Citrobacter', 'Enterobacter', 'Escherichia coli', 'Klebsiella pneumoniae', 'Klebsiella other', 'Morganella', 'Proteus', 'Providencia', 'Pseudomonas aeruginosa', 'Pseudomonas other', 'Raoultella' or 'Serratia' is selected)

☐ Susceptible
☐ Resistant; **KPC:** ☐ Negative ☐ Positive ☐ Unknown
OXA-48: ☐ Negative ☐ Positive ☐ Unknown
New Delhi metallo-beta-lactamase (NDM)/VIM/IMP/Other metallo-beta-lactamase;
☐ Negative ☐ Positive ☐ Unknown

Only if pathogen 'Citrobacter', 'Enterobacter', 'Escherichia coli', 'Klebsiella pneumoniae', 'Klebsiella other', 'Morganella', 'Proteus', 'Providencia', 'Pseudomonas aeruginosa', 'Pseudomonas other', 'Raoultella' or 'Serratia' is selected

Ceftazidime avibactam (caz-avi, avycaz) resistance/susceptibility:
☐ Susceptible ☐ Resistant ☐ Susceptibility unknown

Ceftazidime avibactam+aztreonam resistance/susceptibility:
☐ Susceptible ☐ Resistant ☐ Susceptibility unknown

Meropenem vaborbactam resistance/susceptibility:
☐ Susceptible ☐ Resistant ☐ Susceptibility unknown

Imipenem-cilastatin-relebactam resistance/susceptibility:
☐ Susceptible ☐ Resistant ☐ Susceptibility unknown

Cefiderocol resistance/susceptibility:
☐ Susceptible ☐ Resistant ☐ Susceptibility unknown

☐ Susceptibility unknown

Trimethoprim/sulfamethoxazole resistance/susceptibility: *(Only if pathogen 'Stenotrophomas maltophilia' is selected)*
☐ Susceptible ☐ Resistant ☐ Susceptibility unknown

Sulbactam resistance/susceptibility: *(Only if pathogen 'Acinetobacter baumannii', 'Acinetobacter lwofii' or 'Acinetobacter other' is selected)*
☐ Susceptible ☐ Resistant ☐ Susceptibility unknown

Cefiderocol resistance/susceptibility: *(Only if pathogen 'Acinetobacter baumannii', 'Acinetobacter lwofii' or 'Acinetobacter other' is selected)*
☐ Susceptible ☐ Resistant ☐ Susceptibility unknown

Only if pathogen 'Pseudomonas aeruginosa' is selected

Ceftolozane tazobactam (zerbaxa) resistance/susceptibility:	☐ Susceptible	☐ Resistant	☐ Susceptibility unknown
Ceftazidime resistance/susceptibility:	☐ Susceptible	☐ Resistant	☐ Susceptibility unknown
Cefepime resistance/susceptibility:	☐ Susceptible	☐ Resistant	☐ Susceptibility unknown
Piperacillin tazobactam resistance/susceptibility:	☐ Susceptible	☐ Resistant	☐ Susceptibility unknown
Amikacin resistance/susceptibility:	☐ Susceptible	☐ Resistant	☐ Susceptibility unknown
Ciprofloxacin/levofloxacin resistance/susceptibility:	☐ Susceptible	☐ Resistant (if resistant to any of them)	☐ Susceptibility unknown

If more than 1 bacterial infections, copy and fill-in this table as many times as necessary.

* Indicate the pathogen and sub-type (if applicable) by choosing from the list of pathogens provided in Appendix 2
** Indicate CTCAE term by choosing from the list provided in Appendix 3

COMPLICATIONS SINCE THE LAST REPORT
-- Infectious complications --

Infection with clinical implications: ☐ No ☐ Yes: *(select all that apply during this period)*
- ☐ Symptoms/signs of disease
- ☐ Administration of pathogen-directed therapy

☐ Unknown

Indicate at least 1 location involved during this period:

Localisation 1 (CTCAE term):** _____

Localisation 2 (CTCAE term):** _____

Localisation 3 (CTCAE term):** _____

Extended dataset

Were abnormalities detected upon radiological assessment? *(Only if CTCAE term 'Central nervous system infection', 'Sinusitis infective', 'Liver site infection', 'Esophagus or gastric infection', 'Lower gastrointestinal infection', 'Enteritis infective' , 'Other intra-abdominal infection', 'Splenic infection' or 'Urinary tract infection' is selected)*

☐ No
☐ Yes; **What diagnostic technique was used to detect abnormalities?**
- ☐ MRI
- ☐ CT
- ☐ PET
- ☐ PET CT
- ☐ Ultrasound
- ☐ Other; Specify:_____

☐ Unknown

Radiology showing new or worsening pulmonary infiltrates: *(Only if CTCAE term 'Pneumonia' is selected)*

☐ No
☐ Yes; **What diagnostic technique was used to show pulmonary infiltration?**
- ☐ CT
- ☐ PET
- ☐ Chest X-ray
- ☐ MRI

☐ Unknown

Was a biopsy performed? *(Not applicable if CTCAE term 'Bacteremia'is selected)*

☐ No
☐ Yes; **Date of biopsy:** _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)* ☐ Unknown

Was this pathogen detected in biopsy? ☐ No
☐ Yes; **By what technique was the pathogen detected in biopsy?**
- ☐ Culture
- ☐ Histopathological or cytopathological demonstration
- ☐ Immunohistochemistry
- ☐ PCR
- ☐ Stain

☐ Unknown

☐ Unknown

Was bronchoalveolar lavage (BAL) performed? *(Only if CTCAE term 'Pneumonia' or 'Tracheobronchitis infective' is selected)*

☐ No
☐ Yes; **Date of BAL:** _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)* ☐ Unknown

Was this pathogen detected in BAL? ☐ No
☐ Yes; **By what technique was the pathogen detected in BAL?**
- ☐ Culture
- ☐ PCR
- ☐ Stain

☐ Unknown

☐ Unknown

Was CSF obtained? *(Only if CTCAE term 'Central nervous system infection' is selected)*

☐ No
☐ Yes; **Date of CSF:** _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)* ☐ Unknown

Was this pathogen detected in CSF? ☐ No
☐ Yes; **By what technique was the pathogen detected in CSF?**
- ☐ Culture
- ☐ PCR
- ☐ Stain
- ☐ Serology/antigen in CSF

☐ Unknown

☐ Unknown

If more than 1 bacterial infections, copy and fill-in this table as many times as necessary.

** Indicate CTCAE term by choosing from the list provided in Appendix 3

COMPLICATIONS SINCE THE LAST REPORT
-- Infectious complications --

Extended dataset

Were typical lesions seen on the eye examination? *(Only if CTCAE term'Other eye infection' is selected)*

☐ No ☐ Yes ☐ Unknown

Was the patient transferred to the ICU due to this infection? ☐ No ☐ Yes ☐ Unknown

(if patient died)
Contributory cause of death: ☐ No ☐ Yes ☐ Unknown

If more than 1 bacterial infections, copy and fill-in this table as many times as necessary.

* Indicate the pathogen and sub-type (if applicable) by choosing from the list of pathogens provided in Appendix 2
** Indicate CTCAE term by choosing from the list provided in Appendix 3

COMPLICATIONS SINCE THE LAST REPORT
-- Infectious complications -- continued

Viral infection: ☐ No ☐ Yes ☐ Unknown

New or ongoing: ☐ Newly developed ☐ Ongoing since previous assessment

Start date: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD) only if newly developed* ☐ Unknown

Pathogen*: _____

Infection with clinical implications: ☐ No
☐ Yes***:*(select all that apply during this period)*
- ☐ Symptoms/signs of disease
- ☐ Administration of pathogen-directed therapy(including pre-emptive therapy)

☐ Unknown

Indicate at least 1 location involved during this period:

Localisation 1 (CTCAE term)**: _____

Localisation 2 (CTCAE term)**: _____

Localisation 3 (CTCAE term)**: _____

Extended dataset

Were abnormalities detected upon radiological assessment? *(Only if CTCAE term 'Central nervous system infection', 'Liver site infection', 'Esophagus or gastric infection', 'Lower gastrointestinal infection', 'Enteritis infective' 'Other intra-abdominal infection' or 'Urinary tract infection' is selected)*

☐ No
☐ Yes; **What diagnostic technique was used to detect abnormalities?**
☐ Unknown

- ☐ MRI
- ☐ CT
- ☐ PET
- ☐ PET CT
- ☐ Ultrasound
- ☐ Other; Specify:_____

Radiology showing new or worsening pulmonary infiltrates: *(Only if CTCAE term 'Pneumonia' is selected)*

☐ No
☐ Yes; **What diagnostic technique was used to show pulmonary infiltration?**
☐ Unknown

- ☐ CT
- ☐ PET
- ☐ Chest X-ray
- ☐ MRI

Was a biopsy performed? *(Not applicable if CTCAE term 'Viremia including DNAemia' is selected)*

☐ No
☐ Yes; **Date of biopsy:** _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)* ☐ Unknown

Was this pathogen detected in biopsy? ☐ No
☐ Yes; **By what technique was the pathogen detected in biopsy?**
☐ Unknown

- ☐ Histopathological or cytopathological demonstration
- ☐ Immunohistochemistry
- ☐ Quantitative PCR
- ☐ DNA hybridization

☐ Unknown

Was bronchoalveolar lavage (BAL) performed? *(Only if CTCAE term 'Pneumonia' or 'Tracheobronchitis infective' is selected)*

☐ No
☐ Yes; **Date of BAL:** _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)* ☐ Unknown

Was this pathogen detected in BAL? ☐ No
☐ Yes; **By what technique was the pathogen detected in BAL?**
☐ Unknown

- ☐ PCR
- ☐ Cytology and immunofluorescence (IF)

☐ Unknown

If more than 1 viral infections, copy and fill-in this table as many times as necessary.

* Indicate the pathogen and sub-type (if applicable) by choosing from the list of pathogens provided in Appendix 2
** Indicate CTCAE term by choosing from the list provided in Appendix 3
****Also answer 'Yes' in case of pre-emptive therapy*

COMPLICATIONS SINCE THE LAST REPORT
-- Infectious complications -- continued

Extended dataset

Was CSF obtained? *(Only if CTCAE term 'Central nervous system infection' is selected)*

☐ No
☐ Yes; **Date of CSF:** _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)* ☐ Unknown

Was this pathogen detected in CSF? ☐ No
☐ Yes; **By what technique was the pathogen detected in CSF?**
- ☐ PCR
- ☐ Cytology and immunofluorescence (IF)
- ☐ Serology/antigen in CSF

☐ Unknown

☐ Unknown

Was an endoscopy performed? *(Only if CTCAE term 'Lower gastrointestinal infection' or 'Esophagus or gastric infection' is selected)*

☐ No
☐ Yes; **Were gastrointenstinal lesions documented?** ☐ No ☐ Yes ☐ Unknown
☐ Unknown

Were typical lesions seen on the eye examination? *(Only if CTCAE term 'Retinitis infective' or 'Other eye infection' is selected)*

☐ No ☐ Yes ☐ Unknown

Was haemorrhagic cystitis diagnosed? *(Only if CTCAE term 'Urinary tract infection' is selected)*

☐ No ☐ Yes ☐ Unknown

Was HSV resistance to antiviral drugs documented? *(Only if pathogen 'Herpes simplex virus (HSV)' is selected)*

☐ No ☐ Yes ☐ Unknown

Was the patient transferred to the ICU due to this infection? ☐ No ☐ Yes ☐ Unknown

(if patient died)
Contributory cause of death: ☐ No ☐ Yes ☐ Unknown

If more than 1 viral infections, copy and fill-in this table as many times as necessary.

* Indicate the pathogen and sub-type (if applicable) by choosing from the list of pathogens provided in Appendix 2
** Indicate CTCAE term by choosing from the list provided in Appendix 3

Pre-emptive viral therapy

Extended dataset

(If 'Viral infection' is 'Yes')

Did the patient receive pre-emptive therapy for a viral infection during this follow-up period? ☐ No ☐ Yes

If yes, for what virus? *(select all that apply)* *(Please make sure this viral infection has also been registered in the core dataset viral infection-part above and the CTCAE term 'Viremia including DNAemia' was chosen)*

- ☐ **CMV**
- ☐ **EBV**

Specify each pre-emptive therapy modality administered during this follow-up period for each CMV treatment course

(a new pre-emptive therapy course is defined either as a relapse of CMV after at least 2 weeks without antiviral therapy (success of previous treatment) or change of antiviral therapy due to failure of any reason (see definition at 'Response'-question below))

CMV pre-emptive therapy start date: _ _ _ _ / _ _ / _ _ ***(YYYY/MM/DD)*** ☐ Unknown

Antiviral(s) used:
(Select all that apply)

- ☐ Valganciclovir
- ☐ Ganciclovir intravenous
- ☐ Foscarnet
- ☐ Cidofovir
- ☐ Maribavir
- ☐ CMV-specific T-cells (VST) (Please fill in the additional Cell Infusion Sheet in the appendix)
- ☐ CMV hyperimmune immunoglobulin
- ☐ Leflunomide
- ☐ Artesunate
- ☐ Other drug

In case of refractory CMV , was a resistance test performed? (please see definition in the completion guidelines)

- ☐ No
- ☐ Yes: **Which mutation(s) were identified?**
  - ☐ UL97
  - ☐ UL54
  - ☐ UL56
  - ☐ UL27
  - ☐ No mutation identified
- ☐ Unknown

Response to pre-emptive therapy (address response to this specific treatment modality):

- ☐ Success: (stopping pre-emptive therapy without need for restarting therapeutic dose of the same or another antiviral agent within 2 weeks)
- ☐ Failure: (progression of viremia or stable viral load requiring change or addition of therapy, response followed by rebound (during treatment or in the 2 weeks after end of therapy), progression to disease (during treatment or in the 2 weeks after end of therapy), or unacceptable toxicity)

Viral load at the start (+/- 3 days) of pre-emptive therapy: _____	**Unit** ☐ log 10 IU/mL ☐ IU/mL ☐ copies/mL	☐ Not evaluated
Viral load at the discontinuation (+/- 3 days) of pre-emptive therapy: _____	**Unit** ☐ log 10 IU/mL ☐ IU/mL ☐ copies/mL	☐ Not evaluated

Date of discontinuation of pre-emptive therapy: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

Copy as often as necessary to reflect all episodes that occurred

Pre-emptive viral therapy continued

Extended dataset

Specify each pre-emptive therapy modality administered during this follow-up period for each EBV treatment course
(a new pre-emptive therapy course is defined either as a relapse of EBV after at least 2 weeks without therapy (success of previous treatment) or change of therapy due to failure of any reason (see definition at 'Response'-question below))

EBV pre-emptive therapy start date: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

Therapy used: (EBV)
(Select all that apply)

- ☐ Rituximab or anti-CD20 antibody
- ☐ EBV-specific T-cells (VST) *(Please fill in the additional Cell Infusion Sheet in the appendix)*
- ☐ Reduction of immunosuppression (defined as a sustained decrease of at least 20% of the daily dose of immunosuppressive drugs with the exception of low-dose corticosteriod therapy)
- ☐ Other drug

Response to pre-emptive therapy (address response to this specific treatment modality):

- ☐ Success: (stopping pre-emptive therapy without need for restarting therapeutic dose of the same or another antiviral agent within 2 weeks)
- ☐ Failure: (progression of viremia or stable viral load requiring change or addition of therapy, response followed by rebound (during treatment or in the 2 weeks after end of therapy), progression to disease (during treatment or in the 2 weeks after end of therapy), or unacceptable toxicity)

	Unit	
Viral load at the start (+/- 3 days) of pre-emptive therapy: _____	☐ log 10 IU/mL ☐ IU/mL ☐ copies/mL	☐ Not evaluated
Viral load at the discontinuation (+/- 3 days) of pre-emptive therapy: _____	☐ log 10 IU/mL ☐ IU/mL ☐ copies/mL	☐ Not evaluated

Date of discontinuation of pre-emptive therapy: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

Copy as often as necessary to reflect all episodes that occurred

Treatment of end-organ viral disease

Extended dataset

(If 'Viral infection' is 'Yes')

Did the patient receive treatment for end-organ viral disease during this follow-up period? ☐ No ☐ Yes

If yes, for what virus? (*Please make sure this viral infection has also been registered in the core dataset viral infection-part above*) *(select all that apply)*

- ☐ **CMV**
- ☐ **EBV**
- ☐ **BKV**
- ☐ **ADV**
- ☐ **JCV**
- ☐ **HHV-6**
- ☐ **CARVs** (community acquired respiratory viruses)

Specify each treatment modality given during this follow-up period for each occurrence of CMV disease or change in antiviral therapy due to failure (*see definition at 'Response'-question below*) that occurred

End-organ disease treatment start date: _ _ _ _ / _ _ / _ _ ***(YYYY/MM/DD)*** ☐ Unknown

Antiviral(s) used:

(Select all that apply (More than one modality can be added if the intention is combination therapy and the modalities are started no more than 48 hours apart))

- ☐ Valganciclovir
- ☐ Ganciclovir intravenous
- ☐ Foscarnet
- ☐ Cidofovir
- ☐ Maribavir
- ☐ CMV-specific T-cells (VST) (Please fill in the additional Cell Infusion Sheet in the appendix)
- ☐ CMV hyperimmune immunoglobulin
- ☐ Regular immunoglobulin
- ☐ Leflunomide
- ☐ Artesunate
- ☐ Other drug

In case of refractory CMV , was a resistance test performed? (please see definition in the completion guidelines)

- ☐ No
- ☐ Yes: **Which mutation(s) were identified?**
  - ☐ UL97
  - ☐ UL54
  - ☐ UL56
  - ☐ UL27
  - ☐ No mutation identified
- ☐ Unknown

Response to end-organ disease treatment (address response to this/these specific treatment modality/modalities):

- ☐ Success: (Defined as stopping end-organ disease treatment without the need for restarting the same or other treatment)
- ☐ Failure: (Defined as progression requiring change or addition of end-organ disease treatment, response followed by rebound (worsening symptoms after initial improvement, death or unacceptable toxicity))

Date of discontinuation of end-organ disease treatment: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

Specify each treatment modality given during this follow-up period for each occurrence of EBV disease or change in therapy due to failure (see definition at 'Response'-question below) that occurred

EBV end-organ disease treatment start date: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

Therapy used: (EBV)

*(Select all that apply(*More than one modality can be added if the intention is combination therapy and the modalities are started no more than 48 hours apart)*)*

- ☐ Rituximab or anti-CD20 antibody
- ☐ EBV-specific T-cells (VST) *(Please fill in the additional Cell Infusion Sheet in the appendix)*
- ☐ Reduction of immunosuppression (defined as a sustained decrease of at least 20% of the daily dose of immunosuppressive drugs with the exception of low-dose corticosteriod therapy)
- ☐ Other drug

Response to end-organ disease treatment (address response to this/these specific treatment modality/modalities):

- ☐ Success: (Defined as stopping end-organ disease treatment without the need for restarting the same or other treatment)
- ☐ Failure: (Defined as progression requiring change or addition of end-organ disease treatment, response followed by rebound (worsening symptoms after initial improvement, death or unacceptable toxicity))

Date of discontinuation of end-organ disease treatment: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

Copy as often as necessary to reflect all episodes that occurred

Treatment of end-organ viral disease continued

Extended dataset

Specify each treatment modality given during this follow-up period for each occurrence of BKV disease or change in antiviral therapy due to failure (see definition at 'Response'-question below) that occurred

BKV end-organ disease treatment start date: _ _ _ _ / _ _ / _ _ (YYYY/MM/DD) ☐ Unknown

Antiviral(s) used: (BKV)

(Select all that apply (More than one modality can be added if the intention is combination therapy and the modalities are started no more than 48 hours apart))

- ☐ Cidofovir
- ☐ BKV-specific T-cells (VST) (Please fill in the additional Cell Infusion Sheet in the appendix)

Response to end-organ disease treatment (address response to this/these specific treatment modality/modalities):

- ☐ Success: (Defined as stopping end-organ disease treatment without the need for restarting the same or other treatment)
- ☐ Failure: (Defined as progression requiring change or addition of end-organ disease treatment, response followed by rebound (worsening symptoms after initial improvement, death or unacceptable toxicity))

Date of discontinuation of end-organ disease treatment: _ _ _ _ / _ _ / _ _ (YYYY/MM/DD) ☐ Unknown

Specify each treatment modality given during this follow-up period for each occurrence of ADV disease or change in antiviral therapy due to failure (see definition at 'Response'-question below) that occurred

ADV end-organ disease treatment start date: _ _ _ _ / _ _ / _ _ (YYYY/MM/DD) ☐ Unknown

Antiviral(s) used: (ADV)

(Select all that apply (More than one modality can be added if the intention is combination therapy and the modalities are started no more than 48 hours apart))

- ☐ Cidofovir
- ☐ Brincidofovir
- ☐ Ribavirin
- ☐ Immunoglobulin as treatment (not for replacement)
- ☐ ADV-specific T-cells (VST) (Please fill in the additional Cell Infusion Sheet in the appendix)

Response to end-organ disease treatment (address response to this/these specific treatment modality/modalities):

- ☐ Success: (Defined as stopping end-organ disease treatment without the need for restarting the same or other treatment)
- ☐ Failure: (Defined as progression requiring change or addition of end-organ disease treatment, response followed by rebound (worsening symptoms after initial improvement, death or unacceptable toxicity))

Date of discontinuation of end-organ disease treatment: _ _ _ _ / _ _ / _ _ (YYYY/MM/DD) ☐ Unknown

Specify each treatment modality given during this follow-up period for each occurrence of JCV disease or change in therapy due to failure (see definition at 'Response'-question below) that occurred

JCV end-organ disease treatment start date: _ _ _ _ / _ _ / _ _ (YYYY/MM/DD) ☐ Unknown

Therapy used: (JCV)

(Select all that apply (More than one modality can be added if the intention is combination therapy and the modalities are started no more than 48 hours apart))

- ☐ Cidofovir
- ☐ JCV-specific T-cells (VST) (Please fill in the additional Cell Infusion Sheet in the appendix)
- ☐ Mirtazapine
- ☐ Checkpoint inhibitors

Response to end-organ disease treatment (address response to this/these specific treatment modality/modalities):

- ☐ Success: (Defined as stopping end-organ disease treatment without the need for restarting the same or other treatment)
- ☐ Failure: (Defined as progression requiring change or addition of end-organ disease treatment, response followed by rebound (worsening symptoms after initial improvement, death or unacceptable toxicity))

Date of discontinuation of end-organ disease treatment: _ _ _ _ / _ _ / _ _ (YYYY/MM/DD) ☐ Unknown

Copy as often as necessary to reflect all episodes that occurred

Treatment of end-organ viral disease continued

Extended dataset

Specify each treatment modality given during this follow-up period for each occurrence of HHV-6 disease or change in antiviral therapy due to failure (see definition at 'Response'-question below) that occurred

HHV-6 end-organ disease treatment start date: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

Antiviral(s) used: (HHV-6)

(Select all that apply (More than one modality can be added if the intention is combination therapy and the modalities are started no more than 48 hours apart))

- ☐ Cidofovir
- ☐ HHV-6-specific T-cells (VST) (Please fill in the additional Cell Infusion Sheet in the appendix)
- ☐ Ganciclovir
- ☐ Valganciclovir
- ☐ Foscarnet

Was HHV-6 subtyping done?

- ☐ No
- ☐ Yes; **What HHV-6 subtype was identified?** ☐ HHV-6A ☐ HHV-6B ☐ Unknown
- ☐ Unknown

Was testing for chromosomally integrated HHV-6 done?

- ☐ No
- ☐ Yes; **Was chromosomally integrated HHV-6 present?** ☐ No ☐ Yes ☐ Unknown
- ☐ Unknown

Response to end-organ disease treatment (address response to this/these specific treatment modality/modalities):

- ☐ Success: (Defined as stopping end-organ disease treatment without the need for restarting the same or other treatment)
- ☐ Failure: (Defined as progression requiring change or addition of end-organ disease treatment, response followed by rebound (worsening symptoms after initial improvement, death or unacceptable toxicity))

Date of discontinuation of end-organ disease treatment: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

Specify each treatment modality given during this follow-up period for each occurrence of community acquired respiratory virus (CARV) disease or change in antiviral therapy due to failure (see definition at 'Response'-question below) that occurred

CARV end-organ disease treatment start date: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

Antiviral(s) used: (CARV)

(Select all that apply (More than one modality can be added if the intention is combination therapy and the modalities are started no more than 48 hours apart))

- ☐ Oseltamivir
- ☐ Zanamivir
- ☐ Baloxavir
- ☐ Peramivir
- ☐ Ribavirin
- ☐ Intravenous immunoglobulin (IVIG) for treatment
- ☐ Remdesivir
- ☐ Nirmatrel-Ritonavir

Response to end-organ disease treatment (address response to this/these specific treatment modality/modalities):

- ☐ Success: (Defined as stopping end-organ disease treatment without the need for restarting the same or other treatment)
- ☐ Failure: (Defined as progression requiring change or addition of end-organ disease treatment, response followed by rebound (worsening symptoms after initial improvement, death or unacceptable toxicity))

Date of discontinuation of end-organ disease treatment: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

Copy as often as necessary to reflect all episodes that occurred

COMPLICATIONS SINCE THE LAST REPORT
-- Infectious complications -- continued

Invasive fungal infection: ☐ No ☐ Yes ☐ Unknown

New or ongoing: ☐ Newly developed ☐ Ongoing since previous assessment

Start date: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD) only if newly developed* ☐ Unknown

☐ Yeasts ☐ Moulds

Pathogen*: _____

Extended dataset

Voriconazole resistance/susceptibility: ☐ Susceptible ☐ Resistant ☐ Susceptibility unknown
(Only if pathogen 'Aspergillus flavus', 'Aspergillus fumigatus', 'Aspergillus terreus' or 'Aspergillus other' is selected)

Infection with clinical implications: ☐ No ☐ Yes: *(select all that apply during this period)*
☐ Symptoms/signs of disease
☐ Administration of pathogen-directed therapy
☐ Unknown

Indicate at least 1 location involved during this period:

Localisation 1 (CTCAE term):** _____
Localisation 2 (CTCAE term):** _____
Localisation 3 (CTCAE term):** _____

Extended dataset

Were abnormalities detected upon radiological assessment? *(Only if CTCAE term 'Central nervous system infection', 'Sinusitis infective', 'Liver site infection', 'Esophagus or gastric infection', 'Lower gastrointestinal infection', 'Enteritis infective' , 'Other intra-abdominal infection', 'Splenic infection' or 'Urinary tract infection' is selected)*

☐ No
☐ Yes; **What diagnostic technique was used to detect abnormalities?**
☐ Unknown

☐ MRI
☐ CT
☐ PET
☐ PET CT
☐ Ultrasound
☐ Other; Specify:_____

Radiology showing new or worsening pulmonary infiltrates: *(Only if CTCAE term 'Pneumonia' is selected)*

☐ No
☐ Yes; **What diagnostic technique was used to show pulmonary infiltration?**

☐ CT
☐ PET
☐ Chest X-ray
☐ MRI

Were at least one of the following detected: Nodular lesion/Halo sign/Reverse halo sign/Cavity/Tree in bud/Ground glass/Wedge-shaped and segmental or lobal consolidation:

☐ No
☐ Yes
☐ Unknown

☐ Unknown

Was PCR in blood performed? ☐ No ☐ Yes, negative ☐ Yes, positive ☐ Unknown

(If Yes, negative/Yes, positive)
Date of PCR in blood performed: _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)* ☐ Unknown

(If Yes, positive)

Was the result confirmed by a second test?

☐ No, second PCR in blood not taken
☐ No, second PCR in blood taken and negative
☐ Yes
☐ Unknown

If more than 1 fungal infections, copy and fill-in this table as many times as necessary.

* Indicate the pathogen and sub-type (if applicable) by choosing from the list of pathogens provided in Appendix 2
** Indicate CTCAE term by choosing from the list provided in Appendix 3

COMPLICATIONS SINCE THE LAST REPORT
-- Infectious complications -- continued

Extended dataset

Was a biopsy performed? *(Not applicable if CTCAE term 'Fungemia' is selected)*
- ☐ No
- ☐ Yes; **Date of biopsy:** _ _ _ _/ _ _/ _ _ (YYYY/MM/DD) ☐ Unknown

Was this pathogen detected in biopsy? ☐ No ☐ Yes; **By what technique was the pathogen detected in biopsy?**
- ☐ Culture
- ☐ Histopathological or cytopathological demonstration
- ☐ Immunohistochemistry
- ☐ PCR
- ☐ Fungal stain
- ☐ Unknown

☐ Unknown

Was bronchoalveolar lavage (BAL) performed? *(Only if CTCAE term 'Pneumonia' or 'Tracheobronchitis infective' is selected)*
- ☐ No
- ☐ Yes; **Date of BAL:** _ _ _ _/ _ _/ _ _ (YYYY/MM/DD) ☐ Unknown

Was this pathogen detected in BAL? ☐ No ☐ Yes; **By what technique was the pathogen detected in BAL?**
- ☐ Culture
- ☐ PCR
- ☐ Stain
- ☐ BAL Galactomannan assay
- ☐ Unknown

☐ Unknown

Was CSF obtained? *(Only if CTCAE term 'Central nervous system infection' is selected)*
- ☐ No
- ☐ Yes; **Date of CSF:** _ _ _ _/ _ _/ _ _ (YYYY/MM/DD) ☐ Unknown

Was this pathogen detected in CSF? ☐ No ☐ Yes; **By what technique was the pathogen detected in CSF?**
- ☐ Culture
- ☐ PCR
- ☐ Beta D glucan galactomannan
- ☐ Stain
- ☐ Serology/antigen in CSF
- ☐ Unknown

☐ Unknown

Was sinus fluid sampled? *(Only if CTCAE term 'Sinusitis infective' is selected)*
- ☐ No
- ☐ Yes; **Date of sinus fluid sampling:** _ _ _ _/ _ _/ _ _ (YYYY/MM/DD) ☐ Unknown

Was this fungus detected in sinus fluid? ☐ No ☐ Yes; **By what technique was the fungus detected in sinus fluid?**
- ☐ Culture
- ☐ PCR
- ☐ Fungal stain
- ☐ Unknown

☐ Unknown

Was an endoscopy performed? *(Only if CTCAE term 'Lower gastrointestinal infection' or 'Esophagus or other gastric infection' is selected)*
- ☐ No
- ☐ Yes; **Were gastrointenstinal lesions documented?** ☐ No ☐ Yes ☐ Unknown
- ☐ Unknown

Were typical lesions seen on the eye examination? *(Only if CTCAE term "Retinitis infective' or 'Other eye infection' is selected)*
☐ No ☐ Yes ☐ Unknown

Was the patient transferred to the ICU due to this infection? ☐ No ☐ Yes ☐ Unknown

(if patient died)
Contributory cause of death: ☐ No ☐ Yes ☐ Unknown

If more than 1 fungal infections, copy and fill-in this table as many times as necessary.

* Indicate the pathogen and sub-type (if applicable) by choosing from the list of pathogens provided in Appendix 2
** Indicate CTCAE term by choosing from the list provided in Appendix 3

COMPLICATIONS SINCE THE LAST REPORT
-- Infectious complications -- continued

Parasitic infection: ☐ No ☐ Yes ☐ Unknown

New or ongoing: ☐ Newly developed ☐ Ongoing since previous assessment

Start date: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD) only if newly developed* ☐ Unknown

☐ Protozoa ☐ Helminths

Pathogen*: _____

Infection with clinical implications: ☐ No
☐ Yes: *(select all that apply during this period)*
☐ Symptoms/signs or disease
☐ Administration of pathogen-directed therapy
☐ Unknown

Indicate at least 1 location involved during this period:

Localisation 1 (CTCAE term)**: _____

Localisation 2 (CTCAE term)**: _____

Localisation 3 (CTCAE term)**: _____

Extended dataset

Were abnormalities detected upon radiological assessment? *(Only if CTCAE term 'Central nervous system infection', 'Sinusitis infective', 'Liver site infection', 'Esophagus or gastric infection', 'Lower gastrointestinal infection', 'Enteritis infective' , 'Other intra-abdominal infection', 'Splenic infection' or 'Urinary tract infection' is selected)*

☐ No
☐ Yes; **What diagnostic technique was used to detect abnormalities?**
☐ Unknown

- ☐ MRI
- ☐ CT
- ☐ PET
- ☐ PET CT
- ☐ Ultrasound
- ☐ Other; Specify:_____

Radiology showing new or worsening pulmonary infiltrates: *(Only if CTCAE term 'Pneumonia' is selected)*

☐ No
☐ Yes; **What diagnostic technique was used to show pulmonary infiltration?**
☐ Unknown

- ☐ CT
- ☐ PET
- ☐ Chest X-ray
- ☐ MRI

Was a biopsy performed? *(Not applicable if CTCAE term 'DNAemia for parasitic infection' is selected)*

☐ No
☐ Yes; **Date of biopsy:** _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)* ☐ Unknown

Was this pathogen detected in biopsy? ☐ No
☐ Yes; **By what technique was the pathogen detected in biopsy?**

- ☐ Culture
- ☐ Histopathological or cytopathological demonstration
- ☐ Immunohistochemistry
- ☐ PCR
- ☐ Stain

☐ Unknown

☐ Unknown

If more than 1 parasitic infections, copy and fill-in this table as many times as necessary.

* Indicate the pathogen and sub-type (if applicable) by choosing from the list of pathogens provided in Appendix 2
** Indicate CTCAE term by choosing from the list provided in Appendix 3

COMPLICATIONS SINCE THE LAST REPORT
-- Infectious complications -- continued

Extended dataset

Was bronchoalveolar lavage (BAL) performed? *(Only if CTCAE term 'Pneumonia' or 'Tracheobronchitis infective' is selected)*
- ☐ No
- ☐ Yes; **Date of BAL:** _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)* ☐ Unknown
  - **Was this pathogen detected in BAL?** ☐ No
  - ☐ Yes; **By what technique was the pathogen detected in BAL?**
    - ☐ Culture
    - ☐ PCR
    - ☐ Stain
  - ☐ Unknown
- ☐ Unknown

Was CSF obtained? *(Only if CTCAE term 'Central nervous system infection' is selected)*
- ☐ No
- ☐ Yes; **Date of CSF:** _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)* ☐ Unknown
  - **Was this pathogen detected in CSF?** ☐ No
  - ☐ Yes; **By what technique was the pathogen detected in CSF?**
    - ☐ Culture
    - ☐ PCR
    - ☐ Stain
    - ☐ Serology/antigen in CSF
  - ☐ Unknown
- ☐ Unknown

Were typical lesions seen on the eye examination? *(Only if CTCAE term 'Retinitis infective' or 'Other eye infection' is selected)*
☐ No ☐ Yes ☐ Unknown

Was the patient transferred to the ICU due to this infection? ☐ No ☐ Yes ☐ Unknown

(if patient died)
Contributory cause of death: ☐ No ☐ Yes ☐ Unknown

If more than 1 parasitic infections, copy and fill-in this table as many times as necessary.

* Indicate the pathogen and sub-type (if applicable) by choosing from the list of pathogens provided in Appendix 2
** Indicate CTCAE term by choosing from the list provided in Appendix 3

COMPLICATIONS SINCE THE LAST REPORT
-- Infectious complications -- continued

Infection with unknown pathogen: ☐ No ☐ Yes ☐ Unknown
(for clinical infections without microbiological documentation, like pneumonia, cellulitis, etc.)

New or ongoing: ☐ Newly developed ☐ Ongoing since previous assessment

Start date: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD) only if newly developed* ☐ Unknown

Infection with clinical implications: ☐ No ☐ Yes: (select all that apply)
- ☐ Symptoms/signs or disease
- ☐ Administration of pathogen-directed therapy
- ☐ Unknown

Indicate at least 1 location:

Localisation 1 (CTCAE term)*: _____ ☐ Unknown

Localisation 2 (CTCAE term)*: _____ ☐ Unknown

Localisation 3 (CTCAE term)*: _____ ☐ Unknown

Extended dataset

Were abnormalities detected upon radiological assessment? *(Only if CTCAE term 'Central nervous system infection', 'Sinusitis infective', 'Liver site infection', 'Esophagus or gastric infection', 'Lower gastrointestinal infection', 'Enteritis infective' , 'Other intra-abdominal infection', 'Splenic infection'or 'Urinary tract infection' is selected)*

☐ No
☐ Yes; **What diagnostic technique was used to detect abnormalities?**
☐ Unknown

- ☐ MRI
- ☐ CT
- ☐ PET
- ☐ PET CT
- ☐ Ultrasound
- ☐ Other; Specify:_____

Radiology showing new or worsening pulmonary infiltrates: *(Only if CTCAE term 'Pneumonia' is selected)*

☐ No
☐ Yes; **What diagnostic technique was used to show pulmonary infiltration?**
☐ Unknown

- ☐ CT
- ☐ PET
- ☐ Chest X-ray
- ☐ MRI

Was the patient transferred to the ICU due to this infection? ☐ No ☐ Yes ☐ Unknown

(if patient died)
Contributory cause of death: ☐ No ☐ Yes ☐ Unknown

If more than 1 infections with unknown pathogen, copy and fill-in this table as many times as necessary.

* Indicate CTCAE term by choosing from the list provided in Appendix 3 at page 25

VACCINATIONS

Extended dataset

Was the patient vaccinated with recombinant zoster vaccine (RZV; Shingrix® - GlaxoSmithKline (GSK)) during this follow-up period after the CT treatment took place?

- ☐ No
- ☐ Yes; **Date of first RZV (Shingrix®) vaccination:** _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)* ☐ Unknown
  Date of last RZV (Shingrix®) vaccination: _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)* ☐ Unknown
  Number of doses RZV (Shingrix®) vaccine: _ _ _ _ _ _ _ _ _ _ _ _
- ☐ Unknown

Was the patient vaccinated against Respiratory syncytial virus(RSV) during this follow-up period after the CT treatment took place?

- ☐ No
- ☐ Yes; **What type of RSV vaccine did the patient receive?**
  - ☐ Adjuvant subunit vaccine (Arexvy® - GlaxoSmithKline (GSK))
  - ☐ Unadjuvanted bivalent recombinant RSV vaccine (Abrysvo® - Pfizer)
  - ☐ mRNA-based vaccine (mResvia® - Moderna)

  Date of RSV vaccination : _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)* ☐ Unknown
- ☐ Unknown

Did the patient receive monoclonal antibody against RSV during this follow-up period after the CT treatment took place?

- ☐ No
- ☐ Yes; **What type of RSV antibody did the patient receive?**
  - ☐ Clesrovimab (Enflonsia® - Merck)
  - ☐ Palivizumab (Synagis® - AstraZeneca)
  - ☐ Nirsevimab (Beyfortus® - Sanofi)
  - ☐ Unknown

  Date of monoclonal antibody given: _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)* ☐ Unknown
- ☐ Unknown

SECONDARY MALIGNANCIES AND AUTOIMMUNE DISORDERS

Did a secondary malignancy or autoimmune disorder occur during this follow-up period?

☐ No

☐ Yes: **Was it a secondary malignancy or autoimmune disorder?**

- ☐ Secondary malignancy
- ☐ Autoimmune disorder

Date of diagnosis: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)*

Further details on secondary malignancy and autoimmune disorder: _____
(Both for secondary malignancy and autoimmune disorder)

Was this disease an indication for a subsequent HCT/CT/IST/GT?

- ☐ No (*complete the relevant non-indication diagnosis form*)
- ☐ Yes (*complete the relevant indication diagnosis form*)

☐ Unknown

Secondary malignancies only:

Histologic type *(if applicable)*: _____

Location *(if applicable)*: _____

Secondary malignancy material preserved:
(If a secondary malignancy occurred)

- ☐ No
- ☐ Yes
- ☐ Unknown

Concomitant PBMCs preserved:

- ☐ No
- ☐ Yes
- ☐ Unknown

Was a test on the secondary malignancy material performed?

☐ No

☐ Yes: **Specify:**

- ☐ PCR
- ☐ Flow cytometry
- ☐ Other specify:_____

☐ Unknown

If material tested is 'yes':

What was the outcome of the test?

- ☐ CAR not detected
- ☐ CAR detected: please specify:_____
- ☐ Other specify:_____
- ☐ Unknown

Is the secondary malignancy of T-cell origin?

- ☐ No
- ☐ Yes: please specify:_____
- ☐ Unknown

Please specify the type of secondary malignancy:

☐ Iatrogenic disease in relation with treatments administered prior to cellular therapy cells indication and administration (i.e. cytotoxic agents, targeted therapies, immunotherapies, radiation therapy, etc. Please provide more details below)

☐ Transformation of engineered immune effector cells through insertional mutagenesis or other mechanisms (please provide more details below)

☐ Unknown

Has an investigation to assess the detection of replication competent retrovirus (RCR) in samples of secondary malignancy been conducted? *(If PCR test was performed)*

☐ No

☐ Yes: **What was the outcome?**

- ☐ RCR undetected
- ☐ RCR detected: please specify RCR details: _____
- ☐ Other: please specify: _____

PERSISTENCE OF THE INFUSED CELLS

Was persistence of the infused cellular products assessed since the last follow-up?

☐ No

☐ Yes: **Date of the last assessment:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

Source of cells used for testing:
- ☐ Bone marrow
- ☐ Peripheral blood
- ☐ Tumour
- ☐ Other; specify: _____

Technique used for testing:
- ☐ Molecular (PCR)
- ☐ Flow cytometry
- ☐ Chimaerism
- ☐ Imaging
- ☐ Immunohistochemistry
- ☐ Other; specify: _____

Were immune effector cells (IEC) detected: ☐ No ☐ Yes ☐ Unknown

LAST DISEASE STATUS
Additional Assessments

Disease burden:

LDH level:

☐ Normal

☐ Elevated

☐ Not evaluated

☐ Unknown

Inflammatory state (C-reactive protein [CRP] concentration):

☐ Normal

☐ Elevated

☐ Not evaluated

☐ Unknown

Date of C-reactive protein level assessment: _ _ _ _ */* _ _ */* _ _ ***(YYYY/MM/DD)*** ☐ Unknown

(The date of the most recent assessment should be reported)

(Only if inflammatory state is not elevated at the most recent assesment)

Was the CRP concentration elevated at any time during this follow-up period?

☐ No

☐ Yes

☐ Unknown

Date of maximum C-reactive protein level assessment: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

(The date of the maximum CRP value recorded across all assessments during this follow-up period should be reported; if the maximum CRP value occurred on the same date as the most recent assessment, the same date will be reported twice.)

Maximum CRP concentration: _____ Unit *(check only one)*: ☐ mg/dL ☐ mg/L

(The highest CRP value recorded across all assessments during this follow-up period should be reported)

ADDITIONAL TREATMENTS

Include only systemic treatments designed to consolidate the anti-tumour activity of CT cells, prevent relapse (i.e. administration of immune checkpoint inhibitors). Indicate only treatments that have not been reported at previous follow-up(s).

Did the patient undergo additional treatment during this follow-up period?

☐ No

☐ Yes; ☐ Started in this follow-up period; **complete the "Treatment — non-HCT/CT/GT/IST form and /or the Cell infusion sheet before continuing with 'Additional Cell Infusions'**

☐ Ongoing since previous follow-up

☐ Unknown

ADDITIONAL CELL INFUSIONS

Did the patient receive additional cell infusions *(excluding a new HCT and CT)* **during this follow-up period?**

☐ No

☐ Yes: **Is this cell infusion an allogeneic boost* ?** ☐ No ☐ Yes

** An allogeneic boost is an infusion of cells from the same donor without conditioning, with no evidence of graft rejection.*

Date of the allogeneic boost: _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)*

Is this cell infusion an autologous boost? ☐ No ☐ Yes

Date of the autologous boost: _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)*

☐ Unknown

If this cell infusion is not a boost, attach the Cell Infusion (CI) sheet available in Appendix 6, completing as many sheets as episodes of cell infusion that took place during this interval; then continue below.

Did the patient receive subsequent HCT *(either at your or another centre)***?**

☐ No

☐ Yes

Did the patient receive subsequent cellular therapy *(either at your or another centre)***?**

☐ No

☐ Yes; **Reason for subsequent CT:** ☐ Primary failure
☐ Consolidation
☐ Mitigation of side effects

If the patient had a subsequent HCT/CT, please, make sure that this subsequent treatment is registered using the appropriate treatment form before proceeding.

HOSPITAL ADMISSION

Complete only for Day 100 and 6 Months Follow-Up.

Was inpatient admission and care needed <u>since the last follow-up</u>?

☐ No

☐ Yes; **Number of days in hospital**: _____

☐ Unknown

Was the patient transferred to the intensive care unit (ICU) <u>since the last follow-up</u>?

☐ No

☐ Yes; **Number of days in ICU**: _____

☐ Unknown

RELAPSE/PROGRESSION, RECURRENCE OF DISEASE OR SIGNIFICANT WORSENING

(not relevant for Inborn Errors)

MRD detectable (with any method): (only for Acute leukaemia)

☐ No

☐ Yes: **Date of first detectable MRD:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

☐ Not evaluated

☐ Unknown

Was there a relapse, progression, recurrence of disease or significant worsening of organ function related to the primary disease since last follow-up? *(detected by any method)*

☐ No

☐ Yes; *for every relapse, progression, recurrence, significant worsening complete the questions below*

Type: ☐ Relapse / Recurrence of disease

☐ (Continuous) progression / Significant worsening

Date of relapse/progression/recurrence/worsening: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

Malignant disorders only:

Type of relapse/progression:

Medullary:	☐ No	☐ Yes	☐ Unknown
Extramedullary:	☐ No	☐ Yes	☐ Unknown

If the relapse/progression was extramedullary or both medullary and extramedullary:

Involvement at time of relapse/progression:

Skin:	☐ No	☐ Yes	☐ Not evaluated
CNS:	☐ No	☐ Yes	☐ Not evaluated
Testes/Ovaries:	☐ No	☐ Yes	☐ Not evaluated
Other:	☐ No	☐ Yes; specify: _____	

copy and fill-in this table as many times as necessary.

☐ Unknown

Target expression at relapse after CT:

☐ Absent

☐ Present

☐ Unknown

PATIENT STATUS

Performance status at the last assessment *(check only one)*:

Type of scale used: Score:

Karnofsky/Lansky	☐ 10 ☐ 20 ☐ 30 ☐ 40 ☐ 50 ☐ 60 ☐ 70 ☐ 80 ☐ 90 ☐ 100 ☐ Not evaluated ☐ Unknown
ECOG	☐ 0 ☐ 1 ☐ 2 ☐ 3 ☐ 4 ☐ Not evaluated ☐ Unknown

PREGNANCY AFTER CELLULAR THERAPY

Complete only after 6 Months

Has patient become pregnant or impregnated another person since last follow-up?

☐ No;

Extended dataset

Was there an attempted pregnancy since last follow-up? ☐ No ☐ Yes ☐ Unknown

☐ Yes: **Did the pregnancy result in a live birth?**

- ☐ No; **Date of spontaneous or induced termination**: _ _ _ _ / _ _ / _ _ (YYYY/MM/DD) ☐ Unknown
- ☐ Yes; **Year of birth:** _ _ _ _ (YYYY) **Month of birth:** _ _ (MM) ☐ Unknown
- ☐ Still pregnant at time of follow-up
- ☐ Unknown

Extended dataset

Conception method: ☐ Natural ☐ Assisted ☐ Unknown

☐ Unknown

DISEASE STATUS

Disease specific

Not applicable for Inborn Errors

Disease status at this follow-up or at time of death*: _____

* Indicate the disease status at this follow-up or at time of death corresponding to indication diagnosis by selecting from the list provided in Appendix 1

Appendix 1
Best Response and Disease Status (Disease Specific)

Complete only one section with the main indication diagnosis for which CT was given.

Appendix 1
Best Response and Disease Status (Disease Specific)

Acute leukaemias (AML, PLN, Other)

- ☐ Complete remission (CR)
- ☐ Not in complete remission
- ☐ Not evaluated
- ☐ Unknown

Proceed to next page for Diseases Status section

Chronic leukaemias (CML, CLL, PLL, Other)

Chronic Myeloid Leukaemia (CML):

- ☐ Chronic phase (CP); **Number**: ☐ 1st ☐ 2nd ☐ 3rd or higher ☐ Unknown
  - **Haematological remission:** ☐ No ☐ Yes ☐ Not evaluated ☐ Unknown
  - **Cytogenetic remission:** ☐ No ☐ Yes ☐ Not evaluated ☐ Unknown
  - **Molecular remission:** ☐ No ☐ Yes ☐ Not evaluated ☐ Unknown
- ☐ Accelerated phase; **Number**: ☐ 1st ☐ 2nd ☐ 3rd or higher ☐ Unknown
- ☐ Blast crisis; **Number**: ☐ 1st ☐ 2nd ☐ 3rd or higher ☐ Unknown
- ☐ Not evaluated
- ☐ Unknown

Proceed to next page for Diseases Status section

Chronic Lymphocytic Leukaemia (CLL), Prolymphocytic Leukaemia (PLL) and other chronic leukaemias:

- ☐ Complete remission (CR)
- ☐ Partial remission (PR)
- ☐ Progression: ☐ Resistant to last regimen ☐ Sensitive to last regimen ☐ Unknown
- ☐ Stable disease (no change, no response/loss of response)
- ☐ Relapse
- ☐ Not evaluated
- ☐ Unknown

Proceed to next page for Diseases Status section

Plasma cell neoplasms (PCN)

- ☐ Complete remission (CR)
- ☐ Stringent complete remission (sCR)
- ☐ Very good partial remission (VGPR)
- ☐ Partial remission (PR)
- ☐ Relapse

Number:
- ☐ 1st
- ☐ 2nd
- ☐ 3rd or higher
- ☐ Unknown

- ☐ Progression
- ☐ Stable disease (no change, no response/loss of response)
- ☐ Not evaluated
- ☐ Unknown

Proceed to next page for Diseases Status section

Appendix 1
Best Response and Disease Status (Disease Specific)
continued

Complete only for PCN Disease Status

Was the patient on dialysis during this follow-up period?

☐ Yes; ☐ Started in this follow-up period: **Start date:** _ _ _ _ / _ _ / _ _ (YYYY/MM/DD) ☐ Unknown

☐ Ongoing since previous follow-up

Did dialysis stop? ☐ No
☐ Yes; **End date:** _ _ _ _ / _ _ / _ _ (YYYY/MM/DD) ☐ Unknown
☐ Unknown

☐ No

☐ Unknown

Complete only for AL, CLL and PCN Disease Status

Leukaemias (AL, CLL) and PCN (complete only for patient in CR or sCR)

Minimal residual disease (MRD):
☐ Positive;
☐ Negative
☐ Not evaluated
☐ Unknown

Extended dataset
Date MRD status evaluated: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown

Sensitivity of MRD assay:
☐ $\leq 10^{-6}$
☐ $\leq 10^{-5}$
☐ $\leq 10^{-4}$
☐ $\leq 10^{-3}$
☐ Other; specify: _____
☐ Unknown

Method used:
(select all that apply)
☐ PCR
☐ Flow cytometry
☐ NGS
☐ Other; specify: _____
☐ Unknown

Myeloproliferative neoplasms (MPN), Myelodysplastic neoplasms (MDS), MDS/MPN overlap syndromes

☐ Complete remission (CR)	Number:	☐ 1st ☐ 2nd ☐ 3rd or higher ☐ Unknown
☐ Improvement but no CR		
☐ Primary refractory phase (no change)		
☐ Relapse	Number:	☐ 1st ☐ 2nd ☐ 3rd or higher ☐ Unknown
☐ Progression/Worsening		
☐ Not evaluated		
☐ Unknown		

Appendix 1
Best Response and Disease Status (Disease Specific)
continued

Lymphomas

- ☐ Chemorefractory relapse or progression, including primary refractory disease
- ☐ Complete remission (CR)
- ☐ Partial remission (PR)
- ☐ Stable disease (no change, no response/loss of response)
- ☐ Untreated relapse (from a previous CR) or progression (from a previous PR)
- ☐ Not evaluated
- ☐ Unknown

Technique used for disease assessment:

- ☐ CT scan
- ☐ PET-CT
- ☐ MRI
- ☐ Clinical assessment (for continuous CR)
- ☐ Other; specify: _____
- ☐ Unknown

Solid tumours

- ☐ Complete remission (CR): ☐ Confirmed ☐ Unconfirmed ☐ Unknown
- ☐ First partial remission
- ☐ Partial remission (PR)
- ☐ Progressive disease
- ☐ Relapse: ☐ Resistant ☐ Sensitive ☐ Unknown
- ☐ Stable disease (no change, no response/loss of response)
- ☐ Not evaluated
- ☐ Unknown

Bone marrow failures (incl. AA)

- ☐ Complete remission (CR)
- ☐ Partial remission (PR)
- ☐ Haematological improvement (HI); *NIH partial response*
- ☐ Stable disease (no change, no response/loss of response)
- ☐ Relapse / Progression
- ☐ Not evaluated
- ☐ Unknown

Complete only for Bone marrow failures (incl. AA) Disease Status

Did transfusions stop during the follow-up period?

- ☐ Patient was never transfusion dependent
- ☐ No
- ☐ Yes; **Did the patient return to transfusion dependency afterwards?**
  - ☐ No
  - ☐ Yes; **First transfusion date**: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown (after transfusion free period)
  - ☐ Unknown
- ☐ Ongoing transfusion independence since last follow-up
- ☐ Unknown

Appendix 1
Best Response and Disease Status (Disease Specific)
continued

Autoimmune disorders

☐ No evidence of disease
☐ Improved
☐ Unchanged
☐ Worse
☐ Not evaluated
☐ Unknown

Haemoglobinopathies

Thalassaemia:

Complete only for Thalassemia Best Response

☐ Transfusion independent;	**Date of last transfusion:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown *(after cellular therapy)*
☐ Transfusions required;	**Date of first transfusion:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown *(after cellular therapy)*
☐ Not evaluated	
☐ Unknown	

Complete only for Thalassemia Disease Status

Patient requires transfusions during follow-up period:

☐ No

☐ Yes; ☐ Return to transfusion dependence after cellular therapy or transfusion free period; **Date of first transfusion:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown *(after cellular therapy or transfusion free period)*

☐ Ongoing transfusion dependence since previous assessment

Number of units: ____ ☐ Unknown
(during follow-up period)

Did transfusions stop? ☐ No
☐ Yes; **Date of last transfusion:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown
☐ Unknown

☐ Unknown

Appendix 1
Best Response and Disease Status (Disease Specific)
continued

Haemoglobinopathies

Sickle cell disease:

Complete only for Sickle cell disease Best Response

☐ No return of sickling episodes
☐ Return of sickling episodes; **Date of first episode:** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown *(after cellular therapy)*
☐ Not evaluated
☐ Unknown

Complete only for Sickle cell disease Disease Status

Sickling episodes occur during follow-up period:

☐ No
☐ Yes; ☐ First return of sickling episodes after cellular therapy **Date of first episode :** _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Unknown (after cellular therapy) ☐ Ongoing presence of sickling episodes **Number of SCD episodes**: ____ ☐ Unknown (during follow-up)
☐ Unknown

Other diagnosis

☐ No evidence of disease
☐ Improved
☐ No response
☐ Worse
☐ Not evaluated
☐ Unknown

Appendix 2
-- Pathogens as per EBMT Registry database --

**As defined by the IDSA (Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1-45)*

Bacterial infections

Gram-positive:
. Bacillus (in blood: report only if ≥2 positive separately taken cultures)
. Clostridioides difficile (c difficile/CDT/CDI)
. Clostridium other (NOT difficile)
. Corynebacterium jeikeium
. Corynebacterium other (NOT jeikeium) (in blood: report only if ≥2 positive separately taken cultures)
· Enterococcus faecalis (vancomycin-susceptible)
· Enterococcus faecalis (vancomycin-resistant)
· Enterococcus faecium (vancomycin-susceptible)
· Enterococcus faecium (vancomycin-resistant)
· Listeria monocytogenes
· Nocardia (specify)
. Propionibacterium (in blood: report only if ≥2 positive separately taken cultures)
. Rothia
· Staphylococcus aureus (s aureus/staph aureus) MSSA (methicillin-susceptible)
· Staphylococcus aureus (s aureus/staph aureus) MRSA (methicillin-resistant) vancomycin-susceptible
· Staphylococcus coagulase-negative (in blood: report only if ≥2 positive separately taken cultures)
. Staphylococcus lugdunensis
· Streptococcus pneumoniae (pneumococcus)
· Streptococcus viridans
· Streptococcus other (specify)
· Gram-positive bacteria other (specify)

Gram-negative:
· Acinetobacter baumannii
. Acinetobacter lwoffi (in blood: report only if ≥2 positive separately taken cultures)
. Acinetobacter other (NOT baumannii, NOT lwoffi)
. Bacteroides fragilis
. Bordetella pertussis
. Borrelia
. Brucella
· Campylobacter jejuni
· Citrobacter freundii
. Coxiella burnetti (Q fever)
· Enterobacter cloacae
· Enterobacter other
· Escherichia coli (e coli)
. Fusobacterium
· Haemophilus influenzae (haemophilus influenzae type B/Hib/hemophilus influenzae)
. Haemophilus other (hemophilus)
· Helicobacter pylori
· Klebsiella pneumoniae (carbapenem-susceptible)
. Klebsiella other (NOT pneumoniae) (carbapenem-susceptible)
. Klebsiella (any species) (carbapenem-susceptibility not checked)
· Klebsiella (any species) (carbapenem-resistant)
· Legionella pneumophila
· Morganella morganii
. Micrococcus (in blood: report only if ≥2 positive separately taken cultures)
. Moraxella catarrhalis
· Neisseria gonorrhoeae (gonococcus)
· Neisseria meningitidis (meningococcus)
· Proteus vulgaris
· Providencia
· Pseudomonas aeruginosa (PSA) (carbapenem-susceptible)
· Pseudomonas aeruginosa (PSA) (carbapenem-resistant)
. Pseudomonas aeruginosa (PSA) (carbapenem-susceptibility not checked)
. Pseudomonas other (NOT aeruginosa)
. Raoultella
· Salmonella (specify)
· Serratia marcescens
· Shigella
· Stenotrophomonas maltophilia
· Treponema pallidum (syphilis/lues)
. Yersinia
· Gram-negative bacteria other (specify)

Other bacteria:
· Chlamydia
· Chlamydophila
· Mycobacterium other (specify)
· Mycobacterium tuberculosis (TB)
· Mycoplasma pneumoniae
· Rickettsia
. Ureoplasma
· Bacteria other (specify)

Viral infections:
· Adenovirus (ADV)
. Chikungunya virus
. Crimean-Congo haemorrhagic fever virus (CCHV)
. Dengue virus
· Gastrointestinal viruses:
  o Norovirus
  o Rotavirus
  o Sapovirus
  o Astrovirus
· Hepatotropic viruses:
  o Hepatitis A virus (HAV)
  o Hepatitis B virus (HBV)
  o Hepatitis C virus (HCV)
  o Hepatitis D virus (HDV)
  o Hepatitis E virus (HEV)
· Herpes group:
  o Cytomegalovirus (CMV)
  o Epstein-Barr virus (EBV)
  o Herpes simplex virus (HS/HSV)
  o Herpesvirus 6 (HHV6)
  o Herpesvirus 7 (HHV7)
  o Herpesvirus 8 (HHV8/Kaposi's sarcoma-associated herpesvirus/KSHV/Kaposi)
  o Varicella zoster virus (VZ/VZV/HZV/shingles/zoster/chickenpox)
· Human immunodeficiency virus (HIV)
· Human papilloma viruses (HPV)
. Human T-lymphotropic virus 1 (HTLV-1)
. Human T-lymphotropic virus 2 (HTLV-2)
. Measles virus
. Mumps virus
. Parechovirus
· Parvovirus (parvovirus B-19/B-19)
. Poliovirus
· Polyomaviruses:
  o BK polyomavirus (BKV)
  o JC virus (JCV)
  o Merkel cell virus
· Respiratory viruses:
  o Bocavirus
  o Enterovirus
  o Human coronavirus (excluding SARS-CoV-2 or COVID-19)
  o Influenza A virus (including birdflu)
  o Influenza B virus
  o Human metapneumovirus (hMPV)
  o Parainfluenza
  o Rhinovirus
  o Respiratory syncytial virus (RSV)
  o SARS-CoV-2 virus (COVID-19)
· Rubella virus
. Sandfly viruses (Naples virus/Sicilian virus/Toscana virus/Cyprus virus/Turkey virus/Tehran virus/phlebovirus)
. Tick-borne encephalitis virus (TBE)
. West Nile virus (WNV)
. Yellow fever virus
. Zika virus (ZIKV)
. Viruses other (specify)

Appendix 2
-- Pathogens as per EBMT Registry database -- continued

**As defined by the IDSA* *(Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1-45)*

Fungal infections:

Yeasts:
· Candida albicans
· Candida auris
· Candida other (specify)
· Cryptococcus neoformans
. Geotrichum
. Magnusiomyces
· Pneumocystis jirovecii
. Saccharomyces
. Saprochaete
· Trichosporon
· Yeasts other (specify)

Moulds:
· Aspergillus flavus
· Aspergillus fumigatus
· Aspergillus other (NOT flavus, NOT fumigatus, NOT terreus)
· Aspergillus terreus
· Blastomyces
· Coccidioides
· Dematiaceous fungi / phaeohyphomycosis (specify)
· Fusarium solani
· Fusarium other (NOT solani)
· Galactomannan positive in blood or BAL, without microbiological confirmation of fungal infection
· Histoplasma
· Lomentospora prolificans / scedosporium prolificans
· Mucorales (mucor/rhizomucor/rhizopus/lichteinia) (specify)
· Paracoccidioides
· Scedosporium other (NOT prolificans) (specify)
· Moulds other (specify)

Parasitic infections:

Protozoa:
. Amoeba
· Babesia
· Cryptosporidium
· Giardia
· Leishmania
· Plasmodium (malaria)
· Toxoplasma gondii
· Trypanosoma cruzi
· Protozoa other

Helminths:
. Schistosoma
· Strongyloides stercoralis
· Helminths other

Appendix 3
-- CTCAE term --

CTCAE terms related to infections and infestations (version 5.0.)
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50

Respiratory tract infections
· Pneumonia
· Other respiratory tract infections, please specify:

· Upper respiratory tract infection
· Tracheobronchitis infective
. Pleural infection

Intra-abdominal infections
· Esophagus or gastric infection
· Liver site infection (including biliary tract and gallbladder), please specify:

· Biliary tract or gallbladder infection
· Liver infection

· Lower gastrointestinal infection, please specify:

· Anorectal infection
· Appendicitis infective
. Typhlitis infective

. Enteritis infective, please specify:

· Duodenal infection
· Enterocolitis infective
· Small intestine infection

· Other intra-abdominal infection, please specify:

.Pancreas infection
.Peritoneal infection
.Splenic infection

Skin, soft tissue and muscle infections
. Lymph gland infection
. Skin, soft tissue or muscle infection, please specify:

· Breast infection
· Papulo/pustular rash
· Periorbital infection
. Skin infection (other than periorbital)
. Soft tissue infection (other than periorbital) and muscle infection

Blood infections
· Bacteremia
· Fungemia
· Viremia (including DNAemia)
. DNAemia for parasitic infection

Other infections
. Device-related infection (other than intravascular catheter)
. Post-transplant lymphoproliferative disorder (PTLD)**

Uro-genital tract infections
· Genital infection, please specify:

. Deep genital infection(including cervicitis infective, ovarian/ pelvic/ prostate/ uterine infection)
. Superficial genital infection(including penile/ scrotal / vaginal / vulval infection)

· Urinary tract infection, please specify:

· Cystitis or urethritis infective
. Upper urinary tract infection (e.g. kidney infection)

Nervous system infection
· Central nervous system infection, please specify:

· Encephalitis infective (including abscess)
. Isolated meningitis infective
. Progressive multifocal leukoencephalopathy (PML)*
. Myelitis infective

· Other nervous system infection, please specify:

· Cranial nerve infection
. Other nervous system infection

Cardiovascular infections
. Endocarditis infective
. Other cardiovascular infection, please specify:

· Arteritis infective
. Mediastinal infection
. Myocarditis infective

Head and neck infections (excluding lymph gland)
. Ear infection
· Oral cavity infection, please specify:

· Salivary gland infection
. Other oral cavity structure infection

· Retinitis infective
· Sinusitis infective
Other eye infection, please specify:

Conjunctivitis infective
Corneal infection
Endophthalmitis infective

Osteoarticular infections
· Joint infection
· Bone infection

** Only if pathogen 'JC virus' is selected*
*** Only if pathogen 'Epstein-Barr virus' is selected*

Appendix 4

-- Non-infectious Complications CTCAE term -- No Reporting Required

Non-infectious complications

- Allergic reaction
- All laboratory abnormalities
- All types of pain
- Alopecia
- Blurred vision
- Diarrhoea (enteropathy)
- Dry mouth
- Dyspepsia
- Dysphagia
- Edema
- Esophageal stenosis
- Fatigue
- Flashes
- Gastritis
- Hematologic toxicities
- Hematoma
- Hypertension
- Injection site reaction
- Malaise
- Mucositis
- Sore throat
- Tinnitus
- Vertigo
- Weight loss

Infectious complications

- Minor ophthalmologic bacterial infections
- External otitis treated topically
- Otitis media treated with oral antibiotics
- Isolated lip herpes simplex
- Bacterial tonsillitis or pharyngitis treated orally
- Laryngitis without viral identification managed at home by inhalations or without any intervention
- URTI without viral/bacterial identification managed at home
- Bilateral cervical lymph node enlargement concurrent with URTI that resolved without specific treatment, together with the resolution of URTI
- Local superficial wound infection resolved under topical antibiotics (incl. impetigo)
- Minor skin bacterial infections
- Minor fungal skin infection
- Diaper rash treated with local antifungals
- Candidal balanitis treated topically
- Vaginal candidiasis treated topically or with a single oral dose
- Asymptomatic bacteriuria due to a pathogen not multi-resistant
- Single low urinary tract infection treated orally without need for hospitalisation
- Phlebitis following peripheral intravascular infusion that resolved after intravascular removal without treatment with antibiotics
- Any isolate that is considered part of the normal flora of the place (oral cavity, vagina, skin, stools) except if it carries an antimicrobial resistance that has clinical implications (induce isolation precautions or a pathogen-directed therapy)
- Positive culture without clinical implications

. Neutropenic fever and sepsis of unknown origin

Appendix 6
Cell Infusion Sheet

Chronological number of CI episode for this patient: _____

Date of the first infusion *(within this episode)*: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)*

Number of infusions within this episode (10 weeks): _____
(Count only infusions that are part of the same regimen and given for the same indication)

Source of cells:

- ☐ Allogeneic
- ☐ Autologous

Type of cells:

- ☐ Lymphocytes (DLI)
- ☐ Mesenchymal
- ☐ Fibroblasts
- ☐ Dendritic cells
- ☐ NK cells
- ☐ Regulatory T-cells
- ☐ Gamma/delta cells
- ☐ Virus-specific T-cells (VST)
- ☐ Other; specify: _____

(Only if 'Type of cells: = Virus-specific T-cells (VST))'

Specificity of VST product: ☐ Single-virus specific ☐ Multi-virus specific

If single-virus specific, to which virus? *(Please register this virus in the Infectious complications - Viral infection part and fill in the VST in the 'Pre-emptive viral therapy' or 'Treatment of end-organ viral disease' section)*

- ☐ EBV
- ☐ CMV
- ☐ ADV
- ☐ BKV or JCV
- ☐ HHV-6

If multi-virus specific, to which viruses? *(Please register these viruses in the Infectious complications - Viral infection part and fill in the VST in the 'Pre-emptive viral therapy' or 'Treatment of end-organ viral disease' section)*
(Select all that apply)

- ☐ EBV
- ☐ CMV
- ☐ ADV
- ☐ BKV or JCV
- ☐ HHV-6

Extended dataset

Product origin:

- ☐ In-house manufactured
- ☐ Commercial product;
  - ☐ Tabelecleucel

Donor source; *(Only if 'Source of cells: = Allogeneic')*

- ☐ Related (family)
- ☐ Unrelated

Manufacturing method:

- ☐ In vitro expansion
- ☐ Cytokine capture system (CCS)
- ☐ Multimer sorting

Number of doses per infection episode:

- ☐ 1 dose
- ☐ >1 dose; **Total number of doses:** _____
  Dosing interval (in days): _____

Appendix 6
Cell Infusion Sheet continued

Not applicable for Inborn Errors

Disease status at time of this cell infusion*: _____

* Indicate the disease status corresponding to indication diagnosis by selecting from the list provided in Appendix 1

Indication:
(check all that apply)

- ☐ Planned/protocol
- ☐ Prophylactic
- ☐ Treatment of acute GvHD
- ☐ Treatment of chronic GvHD
- ☐ Treatment PTLD, EBV lymphoma
- ☐ Treatment for primary disease
- ☐ Mixed chimaerism
- ☐ Loss/decreased donor chimaerism
- ☐ Treatment of viral infection other than EBV
- ☐ Poor graft function
- ☐ Infection prophylaxis
- ☐ Other; specify: _____

Only for Acute leukemia donor lymphocyte infusions:

Response to DLI:

- ☐ Complete remission (CR) **MRD status:** ☐ MRD negative ☐ MRD positive ☐ Not evaluated ☐ Unknown
- ☐ Not in CR
- ☐ Not evaluated
- ☐ Unknown